Evidence map›Paper›PMID 16258059›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2005

Isolating gene-corrected stem cells without drug selection.

Seigo Hatada, Larry W Arnold, Tomoko Hatada, John E Cowhig, Dominic Ciavatta, Oliver Smithies

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Sorting and expansion of murine embryonic stem cell colonies using micropallet arrays.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2009
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Seigo HatadaDepartments of Pathology and Laboratory Medicine, and Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina, Chapel Hill, NC 27599-7525, USA.
Larry W Arnold
Tomoko Hatada
John E Cowhig
Dominic Ciavatta
Oliver Smithies
UNC Lineberger Comprehensive Cancer CenterUniversity of North Carolina at Chapel Hill · US

Funding

TARGETED CORRECTION OF FAULTY HUMAN BETA-GLOBIN GENESR01HL037001 · NHLBI · UNIVERSITY OF WISCONSIN MADISON · PI SMITHIES, OLIVER · 1986 to 2004
$3.0M
Genetic Control of Protein Structure and SynthesisR01HL071266 · NHLBI · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI SMITHIES, OLIVER · 2002 to 2005
$1.5M
NHLBI NIH HHS HL-37001NHLBI NIH HHS HL-71266NHLBI NIH HHS R01 HL037001NHLBI NIH HHS R01 HL071266
6 · The paper itself

Abstract

Progress in isolating stem cells from tissues, or generating them from adult cells by nuclear transfer, encourages attempts to use stem cells from affected individuals for gene correction and autologous therapy. Current viral vectors are efficient at introducing transgenic sequences but result in random integrations. Gene targeting, in contrast, can directly correct an affected gene, or incorporate corrective sequences into a site free from undesirable side effects, but efficiency is low. Most current targeting procedures, consequently, use positive-negative selection with drugs, often requiring >/=10 days. This drug selection causes problems with stem cells that differentiate in this time or require feeder cells, because the feeders must be drug resistant and so are not eliminated by the selection. To overcome these problems, we have developed a procedure for isolating gene-corrected stem cells free from feeder cells after 3-5 days culture without drugs. The method is still positive-negative, but the positive and negative drug-resistance genes are replaced with differently colored fluorescence genes. Gene-corrected cells are isolated by FACS. We tested the method with mouse ES cells having a mutant hypoxanthine phosphoribosyltransferase (Hprt) gene and grown on feeder cells. After 5 days in culture, gene-corrected cells were obtained free from feeder cells at a "purity" of >30%, enriched >2,000-fold and with a recovery of approximately 20%. Corrected cells were also isolated singly for clonal expansion. Our FACS-based procedure should be applicable at small or large scale to stem cells that can be cultured (with feeder cells, if necessary) for >/=3 days.

Indexed as

Gene TargetingGenetic TherapyAnimalsCell SeparationFlow CytometryGreen Fluorescent ProteinsHypoxanthine PhosphoribosyltransferaseMiceStem CellsGreen Fluorescent ProteinsHypoxanthine Phosphoribosyltransferase

Identifiers

PMID16258059
PMCPMC1274242
OpenAlexW2032464869

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.